BIOMAT Database Logo BIOMAT Database Logo

Cell-mediated immunity in acute nonlymphocytic leukemia: relationship to host factors, therapy, and prognosis. 1974

W H Greene, and S C Schimpff, and P H Wiernik

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007948 Leukemia, Monocytic, Acute An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES. Leukemia, Monoblastic, Acute,Leukemia, Myeloid, Acute, M5,Leukemia, Myeloid, Schilling-Type,Monoblastic Leukemia, Acute,Monocytic Leukemia, Acute,Myeloid Leukemia, Acute, M5,Myeloid Leukemia, Schilling-Type,Leukemia, Acute Monocytic,Leukemia, Myeloid, Schilling Type,Acute Monoblastic Leukemia,Acute Monoblastic Leukemias,Acute Monocytic Leukemia,Acute Monocytic Leukemias,Leukemia, Schilling-Type Myeloid,Leukemias, Acute Monoblastic,Leukemias, Acute Monocytic,Monoblastic Leukemias, Acute,Monocytic Leukemias, Acute,Myeloid Leukemia, Schilling Type,Schilling-Type Myeloid Leukemia
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009578 Nitrobenzenes BENZENE derivatives carrying nitro group substituents.
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions

Related Publications

W H Greene, and S C Schimpff, and P H Wiernik
Blast cell kinetics and prognosis in acute nonlymphocytic leukemia.
January 1980, Leukemia research,
W H Greene, and S C Schimpff, and P H Wiernik
[Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
December 2007, Zhongguo shi yan xue ye xue za zhi,
W H Greene, and S C Schimpff, and P H Wiernik
The relationship of cellular immunity to prognosis in acute leukemia.
February 1977, Acta medica Okayama,
W H Greene, and S C Schimpff, and P H Wiernik
Therapy of secondary acute nonlymphocytic leukemia.
May 1983, The New England journal of medicine,
W H Greene, and S C Schimpff, and P H Wiernik
Cell-mediated immunity in human acute leukemia.
January 1975, Bibliotheca haematologica,
W H Greene, and S C Schimpff, and P H Wiernik
Host defence factors and prognosis in hairy cell leukemia.
January 1982, Leukemia research,
W H Greene, and S C Schimpff, and P H Wiernik
Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia.
September 1990, Blood,
W H Greene, and S C Schimpff, and P H Wiernik
Cell-mediated and humoral immune response to acute leukemia cells and soluble leukemia antigen--relationship to immunocompetence and prognosis.
June 1973, National Cancer Institute monograph,
W H Greene, and S C Schimpff, and P H Wiernik
Cell cycle characteristics in acute nonlymphocytic leukemia.
February 1988, Blood,
W H Greene, and S C Schimpff, and P H Wiernik
Histologically proven leukemia cutis carries a poor prognosis in acute nonlymphocytic leukemia.
January 1987, Cutis,
Copied contents to your clipboard!